Share
Market Research Report

PHAGE THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By ProductMonophage therapy · Phage cocktails · Engineered/recombinant phages · Phage derived enzymes (e.g., endolysins) · and Combination products (phage + antibiotic or adjunct)
  • By Target PathogenGram negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella spp., Klebsiella pneumoniae, Other Gram‐negative bacteria) and Gram positive bacteria (Gram‑positive bacteria, Staphylococcus aureus, Streptococcus spp., Other Gram‐positive bacteria, Mixed/other pathogens)
  • By Disease IndicationUrinary tract infections (UTIs) · Skin and wound infections · Bone and joint/implant associated infections · Respiratory tract infections (including cystic fibrosis) · Gastrointestinal infections · Bloodstream/sepsis infections · Biofilm related chronic infections · and Other indications
  • By Route of AdministrationOral · Topical/dermal · Injectable/intravenous (IV/IM) · Inhalation/nebulized · Local instillation (e.g., bladder, wound cavity) · and Other routes
  • By End UserHospitals and specialty clinics · Research institutes and academic centers · Ambulatory care/outpatient clinics · and Others (Veterinary clinics)
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In01 Apr 2026
  • Report CodeCMI8994
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Product Insights (Revenue, USD Bn, 2021 - 2033)

    • Monophage therapy
    • Phage cocktails
    • Engineered/recombinant phages
    • Phage‑derived enzymes (e.g., endolysins)
    • Combination products (phage + antibiotic or adjunct)

  • Target Pathogen Insights (Revenue, USD Bn, 2021 - 2033)

    • Gram‑negative bacteria
      • Escherichia coli
      • Pseudomonas aeruginosa
      • Salmonella spp.
      • Klebsiella pneumoniae
      • Other Gram‐negative bacteria
    • Gram‑positive bacteria
      • Staphylococcus aureus
      • Streptococcus spp.
      • Other Gram‐positive bacteria
      • Mixed/other pathogens

  • Disease Indication Insights (Revenue, USD Bn, 2021 - 2033)

    • Urinary tract infections (UTIs)
    • Skin and wound infections
    • Bone and joint/implant‑associated infections
    • Respiratory tract infections (including cystic fibrosis)
    • Gastrointestinal infections
    • Bloodstream/sepsis infections
    • Biofilm‑related chronic infections
    • Other indications

  • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)

    • Oral
    • Topical/dermal
    • Injectable/intravenous (IV/IM)
    • Inhalation/nebulized
    • Local instillation (e.g., bladder, wound cavity)
    • Other routes

  • End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospitals and specialty clinics
    • Research institutes and academic centers
    • Ambulatory care/outpatient clinics
    • Others (Veterinary clinics)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa